NDC 51672-1402-08 - Calcipotriene and Betamethasone Dipropionate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 51672-1402
- Requested NDC
- 51672-1402-08
- Package NDCs from labels
- 51672-1402-4, 51672-1402-8, 51672-1402-08
- Manufacturer
- Sun Pharmaceutical Industries, Inc. | Sun Pharma Canada Inc.
- Effective date
- 2025-07-01
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| MINERAL OIL - Sun Pharmaceutical Industries, Inc. | Sun Pharma Canada Inc. | Sun Pharmaceutical Industries, Inc. | Sun Pharma Canada Inc. | 2025-07-01 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51672-1402-4 | Calcipotriene and Betamethasone Dipropionate | 60 g in 1 BOTTLE | SUSPENSION | 60 | 2 | |
| 51672-1402-4 | Calcipotriene and Betamethasone Dipropionate | 1 in 1 CARTON | SUSPENSION | 1 | 2 | |
| 51672-1402-8 | Calcipotriene and Betamethasone Dipropionate | 60 g in 1 BOTTLE | SUSPENSION | 60 | 2 | |
| 51672-1402-8 | Calcipotriene and Betamethasone Dipropionate | 2 in 1 CARTON | SUSPENSION | 2 | 2 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 51672-1402 | CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE SUSPENSION [TARO PHARMACEUTICALS U.S.A., INC.] | 1 | Current NDC, Legacy NDC, 4 package rows | 20200904_1d0ab2e6-1ab1-4d3e-ad55-7fa26446f191.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TheraPlus Plus | PHENYLEPHRINE HCI | Zhejiang Jingwei Pharmaceutical Co., Ltd. | edf9f8d5-f55d-4c31-adfb-ba77ca24cc3d | 2023-10-25 | Warnings | T5L8T28FGP |
| Clotrimazole and Betamethasone Dipropionate | CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE | A-S Medication Solutions | 5ca32ede-b546-4b65-90d6-c69add760522 | 2023-09-28 | Warnings, Adverse reactions | 826Y60901U |
| Vitalipid N | VITAMIN A PALMITATE, ERGOCALCIFEROL, .ALPHA.-TOCOPHEROL, DL-, PHYTONADIONE | Fresenius Kabi USA, LLC | 704119cc-d2ad-408a-b213-fe232f7fe2ba | 2023-09-07 | 7QWA1RIO01 | |
| ANUBISMED | HA HYALURONIC | ANUBIS COSMETICS SL | eac771e2-4c1b-3808-e053-2995a90ac5fc | 2023-09-05 | Warnings | 1P9D0Z171K |
| AnubisMed | SPF 50 BROAD SPECTRUM PROTECTION FLUID EMULSION | ANUBIS COSMETICS SL | e99d92c4-8768-9c0a-e053-2a95a90a609e | 2023-09-05 | Warnings | 1P9D0Z171K |
| Anubis Barcelona Protective Line | ETHYLHEXYL METHOXYCINNAMATE, BUTYL METHOXYDIBENZOYLMETHANE, ETHYLHEXYL SALICYLATE, OCTOCRYLENE | ANUBIS COSMETICS SL | ec83846f-11c0-8f59-e053-2995a90ab9d2 | 2023-09-01 | Warnings | 1P9D0Z171K |
| Anubis Barcelona Regul Oil | CETEARYL ETHYLHEXANOATE, PROPYLENE GLYCOL, GLYCERYL STEARATE SE | ANUBIS COSMETICS SL | eb68c3ab-7835-1a1c-e053-2995a90a0d66 | 2023-09-01 | Warnings | 1P9D0Z171K |
| Anubis Barcelona Spa Line | ORYZA SATIVA (RICE) STARCH, PERLITE, PALMITIC ACID | ANUBIS COSMETICS SL | eb01a962-ab38-18ec-e053-2995a90acdeb | 2023-09-01 | Warnings | 1P9D0Z171K |
| Anubis Barcelona Regul Oil | PROPYLENE GLYCOL, GLYCERYL STEARATE SE, HUMULUS LUPULUS (HOPS) CONE EXTRACT | ANUBIS COSMETICS SL | eb7c418b-8bee-26a3-e053-2a95a90a4e96 | 2023-09-01 | Warnings | T5L8T28FGP |
| betamethasone dipropionate | BETAMETHASONE DIPROPIONATE | Viona Pharmaceuticals Inc | 9adfb030-17c3-46eb-bf85-a90cabafd367 | 2023-08-07 | Adverse reactions | 826Y60901U |
| Betamethasone Dipropionate | BETAMETHASONE DIPROPIONATE | A-S Medication Solutions | fe946b6d-2b6d-490b-8d63-c865e1c43321 | 2023-07-31 | Adverse reactions | 826Y60901U |
| Calcipotriene and Betamethasone Dipropionate | CALCIPOTRIENE, BETAMETHASONE DIPROPIONATE | Bryant Ranch Prepack | d4b301c5-704a-406d-9d9c-74f006334f8a | 2023-07-17 | Warnings, Adverse reactions | 143NQ3779B 826Y60901U |
| Betamethasone Dipropionate | BETAMETHASONE DIPROPIONATE | A-S Medication Solutions | 0aaa5de4-442b-4184-8378-ea47831e9663 | 2023-07-06 | Adverse reactions | 826Y60901U |
| Clotrimazole and Betamethasone Dipropionate | CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE | A-S Medication Solutions | b3f69dc2-2b88-4866-baea-aa3b3ed84fb1 | 2023-05-16 | Warnings, Adverse reactions | 826Y60901U |
| Betamethasone Dipropionate | BETAMETHASONE DIPROPIONATE | Padagis Israel Pharmaceuticals Ltd | 7bd2646c-f34a-4824-8f66-c41e77db19d2 | 2023-03-31 | Warnings, Adverse reactions | 826Y60901U |
| Betamethasone Dipropionate | BETAMETHASONE DIPROPIONATE | A-S Medication Solutions | 7da1c732-3477-4031-b776-149bd5ceea27 | 2023-03-06 | Adverse reactions | 826Y60901U |
| Betamethasone Dipropionate | BETAMETHASONE DIPROPIONATE | Actavis Pharma, Inc. | aa3f4012-7597-422d-8bcc-00102780a152 | 2023-02-28 | Adverse reactions | 826Y60901U |
| Betamethasone Dipropionate | BETAMETHASONE DIPROPIONATE | Actavis Pharma, Inc. | af8317d7-b280-4f40-ad88-802f99d33d78 | 2023-02-20 | Warnings, Adverse reactions | 826Y60901U |
| Calcipotriene | CALCIPOTRIENE | Prasco Laboratories | 377eafda-737c-4ba2-9ec5-61209b8814ed | 2022-12-12 | Warnings, Adverse reactions | 143NQ3779B |
| Calcipotriene and Betamethasone Dipropionate | CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE | Prasco Laboratories | d9493e66-251c-426c-90a8-1bf1e526ab85 | 2022-12-12 | Warnings, Adverse reactions | 826Y60901U |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.